Stem cells have received a great deal of attention for their clinical and therapeutic potential for treating human diseases and disorders. Recent studies have shown that it is possible to genetically engineered stem cells (GESTECs) to produce suicide enzymes that convert non-toxic prodrugs to toxic metabolites, selectively migrate toward tumor sites and reduce tumor growth. In this study, we evaluated whether these GESTECs are capable of migrating to hepatocarcinoma cells and examined the potential therapeutic efficacy of gene-directed enzyme prodrug therapy against liver cancer cells in cellular and animal models. A modified transwell migration assay was performed to determine the migratory capacity of GESTECs to Hep3B hepatocarcinoma cells. GESTECs, that is, HB1. 
INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death in the world. 1 Every year, 560 000 people are diagnosed with HCC and the same number die of liver cancer worldwide. 2 The incidence of HCC is rising, 3 and it is therefore becoming an important issue in the world. Despite significant improvements in diagnostic methods, treatments and perioperative care for HCC, the prognosis is unsatisfactory due in part to the high incidence of recurrence. Although chemotherapy has an important role in the treatment of HCC, a standard treatment regimen has not yet been established because of resistance of these tumors to anticancer drugs and side effects. 4 In order to enhance the effectiveness of therapeutics for treating liver cancers, novel strategies are required. 2 5-Fluorouracil (5-FU) has been used as a chemotherapeutic agent for treating the majority of solid tumors. However, the side effects of this drug are serious, such as gastrointestinal toxicities or hematological side effects. 5 Therefore, 5-FU therapy strategies associated with fewer side effects are demanded, and recently 'molecular chemotherapy' has been proposed. 6, 7 'Molecular chemotherapy' is based on the theory of targeting therapeutic suicide gene delivery using a cell-based system. As neural stem cells (NSCs) are able to target tumor cells, molecular therapies using these cells can be used to produce antitumor effects in tumor lesions. 8, 9 As gene/prodrug systems can be designed to more selectively target tumor cells than normal cells, 10 the application of enzyme/ prodrug systems to minimize side effects has received much attention. The cytosine deaminase (CD)/5-fluorocytosine (5-FC) system, 11--13 one of the gene-directed enzyme/prodrug therapies (GEPT), metabolically converts non-toxic 5-FC into the toxic metabolite 5-FU 14 and inhibits DNA synthesis in cancer cells. 15 The CD/5-FC GEPT system has been applied to several types of cancers including clinical trials for colorectal and prostate cancers. 13,16--18 The application of prodrugs seems to reduce the toxicity in normal tissues, but there are potential problems with exogenous enzyme delivery for selectively targeting tumor cells.
Stem cells have recently received a great deal of attention for their clinical and therapeutic potential for treating human cancers. For instance, NSCs may have great tropic and therapeutic potential for human malignant tumors such as medulloblastomas and gliomas, 19--21 suggesting that enzyme/prodrug therapy using NSCs can be a potent delivery system to specifically target and eradicate tumor cells following systemic prodrug administration. HB1.F3, a new cell line of human NSCs immortalized using a retroviral vector carrying v-myc oncogene, has been generated from fetal telencephalon tissues at 14 weeks. 22 This clonally isolated and multipotent human NSC line has the ability to selfrenew, carries the normal human karyotype 46 XX and differentiates into cells of neuronal and glial lineages both in vivo and in vitro. 23 In addition to the therapeutic potential of these NSCs to treat brain disorders, their inherent migratory and tumor-tropic properties represent a novel and potentially powerful approach for the treatment of invasive tumors. 24 As a delivery vehicle for targeting tumor cells and disseminating therapeutic gene products throughout tumor sites, these therapeutic NSCs may solve major obstacles facing current gene therapy strategies by selectively infiltrating tumor masses. Human NSCs generated from a single clone can be engineered to stably express a therapeutic suicide gene (that is, CD) to activate the prodrug, 5-FC, because they are homogeneous and can be expanded to large numbers in vitro. HB1.F3 cells, the parental cell line of HB1.F3.CD cells, migrate to subcutaneous xenografts of diverse types of solid tumors including prostate tumors, breast tumors, melanomas, gliomas and neuroblastomas, indicating that these cell lines do not possess a tissue-specific homing tendency but could be therapeutically useful because of their tendency to migrate to tumor tissues in general. 20 In this study, we investigated whether genetically engineered stem cells (GESTECs) have a significant migrating capacity for selectively targeting human liver cancers, as well as the therapeutic value of a suicide/prodrug system in liver cancer therapy.
Recently, it has been reported that the combination of interferon (IFN) and chemotherapeutic drugs resulted in excellent outcomes. 25 Type I IFNs, such as IFN-alpha (IFN-a) and IFN-beta (IFN-b), have been shown to have highly suppressive effects on hepatocellular carcinogenesis by inhibition of cell cycle progression at the G1, S or G2/M phase with or without apoptosis induction. 26 ,27 IFN-b shows the strongest effects, so in this study we also investigated whether IFN-b produces synergetic therapeutic effects in the CD/5-FC/IFN-b GEPT system (a doublepunch method: chemotherapy consisting of the suicide gene/ prodrugs coupled with 'immuno-therapy' using IFN-b) compared with the CD/5-FC GEPT system. Thus, this study was performed to explore the tumor-tropic effects of HB1.F3.CD and HB1.F3.CD.IFN-b cells along with antitumor effects of these stem cells and the prodrug 5-FC. Furthermore, we examined the possible synergistic effects of HB1.F3.CD with IFN-b, a 'double-punch' method, as a potential therapeutic system to selectively treat human hepatocarcinoma.
MATERIALS AND METHODS

Cell culture
The human liver cancer cell line Hep3B (Korean Cell Line Bank, Seoul, Korea) and the bovine fibroblast (bovine FB; obtained from Chungbuk National University, Cheongju, Korea) cell line were cultured in Dulbecco's modified Eagle's medium (DMEM) (PAA Laboratories GmbH, Linz, Austria) supplemented with 10% fetal bovine serum (FBS; PAA Laboratories), 1% antibiotics (penicillin G and streptomycin; Cellgro Mediatech, Manassas, VA), 1% HEPES (Invitrogen Life Technologies, Carlsbad, CA) and 0.1% of the antimycoplasmal agent Plasmocin (Invivogen, San Diego, CA) at 37 1C in a humidified atmosphere of 5% CO 2 --95% air. In addition, immortalized human NSCs, HB1.F3, HB1.F3.CD producing Escherichia coli (E. coli) CD and HB1.F3.CD.IFN-b producing CD and IFN-b, were cultured in the same condition. The cells were trypsinized with 0.05% trypsin/0.02% EDTA (PAA Laboratories).
RNA extraction and reverse transcriptase-PCR
Total RNA extracts were prepared using TriZol Reagent (Invitrogen Life Technologies) and reverse transcribed from 1 mg of total RNA into complementary DNA using M-MLV RT (iNtRON Biotechnology, Sungnam, Kyeonggido, Korea) following the manufacturer's protocols. PCR was conducted to amplify the bacterial CD gene and IFN-b with the primer sequences based on the published sequence of the gene.
14 Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to confirm equal loading. PCR amplification of chemoattractant factors (ligands) and GAPDH a positive control, was performed for 30 cycles. The sense/ antisense primers and the predicted sizes of the PCR products are presented in Table 1 and have been previously described. ) was added to each well and the plates were incubated for 4 h at 37 1C. Supernatants were removed and 100 ml of dimethylsulfoxide (99.0%; Junsei Chemical, Tokyo, Japan) was added to each well to dissolve the resultant formazan crystals. Optical densities were measured at 540 nm using an ELISA-Reader (VERSA man, Molecular Devices, CA). MTT assays were carried out in triplicate.
In vitro migration assay
To investigate whether GESTECs are capable of migrating to liver cancer cells, Hep3B cells (1 Â 10 5 cells per well) and bovine FB cells (control, 1 Â 10 5 cells per well) were plated in 24-well plate contained DMEM medium and incubated for 24 h. The medium was changed to serum-free DMEM and the cells were incubated for another 24 h. Transwell plates (8 mm; BD Biosciences, Dickinson, USA) coated with fibronectin (250 mg ml --1 ; Sigma-Aldrich) were placed in the 24-well plates and CM-DiI (Invitrogen Life Technologies) pre-stained HB1.F3.CD or HB1.F3.CD.IFN-b cells were plated in the upper chambers of the transwell plates at a density of 1 Â 10 5 cells per well in serum-free medium and cultured for 24 h at 37 1C. DAPI (4 0 , 6-diamidino-2-phenylindole; Invitrogen Life Technologies) was added to the lower wells at 200 ng ml --1 and the plates were incubated for 10 min at 37 1C and then washed with PBS. The transwell membrane was then scraped off to remove cells that had not migrated into the membrane. The cells stained with CM-DiI and DAPI were examined by fluorescence microscopy (IX71 Inverted Microscope, Olympus, Tokyo, Japan).
In vivo animal models per day) was administered through intraperitoneal injection every day for 14 days. The stem cells were once again injected to animal models and 5-FC was administered for another 2 weeks. Two days after the final treatment of 5-FC, the animals were killed and tumor mass was harvested for analysis.
Histopathological analysis
Tumor mass excised from animal models was washed with sterilized saline and fixed in 10% normal formalin solution (OCI, Seoul, Korea). A fixed mass was sliced 4--6 mm thick, dehydrated and embedded in paraffin. Paraffin blocks were cut into 3 mm thick sections and sectioned tissue slides were dried at room temperature. After rehydration, tissue sections were stained with hematoxylin and eosin (Sigma-Aldrich), dehydrated, mounted and observed by light microscopy (BX51 model, Olympus).
Fluorescent analysis
Before their injection into mice, the stem cells were previously stained with CM-Dil, a cell tracker, according to the manufacturer's protocol. Tissue slides of tumor sections were prepared as in hematoxylin and eosin staining, hydrated and fixed in 10% normal formalin (OCI) solution for 10 min. After PBS washing two times, DAPI solution (200 ng ml --1 ) was treated to stain cellular nuclei for 10 min at 37 1C. Slides were mounted with coverslips and observed by a fluorescence microscopy (IX71 inverted microscopy, Olympus).
Statistical analysis
In vitro results of three independent experiments by MTT assay or the results of in vivo animal experiment were presented as mean±s.d. or mean±s.e.m., respectively. A statistical analysis was performed using a one-way analysis of variance test. Po0.05 was considered statistically significant. Migratory effect of stem cell in animal experiment In in vitro transwell assay, we confirmed that HB1.F3.CD or HB1.F3.CD.IFN-b cells migrated more effectively to liver cancer cells compared with primary cells. We measured the tumor-tropic effect of these GESTECs in hepatocarcinoma xenografted mice through fluorescent analysis. As a result, a large number of CM-DiI pre-stained stem cells observed as red fluorescence were found on tumor mass (Figure 6b ). However, a negative control showed no red fluorescence. Therefore, these stem cells have tumorspecific migratory capacity and properly position on tumor site where they exert therapeutic activity by CD or IFN-b for targeting hepatocarcinoma.
RESULTS
Confirmation
DISCUSSION
In another study, it appeared that immortalized GESTECs have advantages that may be useful for gene therapy of cancer. 23, 28 An in vitro migration assay and in vivo administration of NSCs into tumor-bearing mice showed that stem cells have the ability to selectively track tumor cells and inhibit tumor growth. 21, 29 A recent study also reported that CD-producing NSCs (HB1.F3.CD cells), which convert the non-toxic 5-FC prodrug to the antitumor toxic 5-FU, selectively migrate to tumor cells and have a therapeutic effects against brain tumors. 20 This shows that NSCs have selective tumor-tropic migrating abilities and can be used as therapeutic gene delivery vehicles for treating various tumors.
The CD/5-FC-derived GEPT system has been tested as a therapy for some types of cancers including those in breast, prostate and colon, 13, 18, 30 but the effect of GESTECs on many other types of cancer cells remains largely unknown. Thus, in this study we examined whether GESTECs expressing CD and CD.IFN-b can be used to selectively treat liver cancer. First, we performed a modified transwell migration assay to examine whether these GESTECs expressing CD or CD.IFN-b are capable of migrating to liver cancer cells. These stem cells actively migrated toward Hep3B cells with tumorigenicity compared with bovine FBs with nontumorigenicity as a control, suggesting that these GESTECs likely respond to chemoattractant factors secreted by liver cancer cells. These results are in agreement with a previous report demonstrating that GESTECs migrate to brain tumors in an animal model. 31 Additionally, HB1.F3 cells, the parent cell line of the HB1.F3.CD and HB1.F3.CD.IFN-b cell lines, migrate to subcutaneous xenografts of diverse solid tumors including prostate tumors, breast tumors, melanomas, gliomas and neuroblastomas, indicating that these cell lines do not possess a tissue-specific homing tendency, and therefore might be exploited for therapeutic use in the treatment of many types of cancer. 20 Although several factors such as SCF/c-Kit, stromal cell-derived factor-1/CXCR4 and VEGF/VEGF receptor 2 (VEGFR2) have a chemoattractive role in tumor cells, 32--36 the molecular mechanism underlying the tumor tropism of GESTECs is not clearly understood. Thus, we further examined the expression of these genes in liver cancer cells and found that chemoattractant ligands and receptors (that is, SCF, CXCR4 and VEGF) were highly expressed in Hep3B cells. Chemoattractant ligands and their receptors expressed by tumor cells may have a role in the growth of tumor cells in an autocrine and paracrine manner. For instance, CXCR4 is a receptor in hepatocarcinoma cells, and induces the cell proliferation or bone metastasis by recognizing stromal cellderived factor-1 (ligand). 37 Although we have not confirmed the expression of CXCR4 ligand (stromal cell-derived factor-1), we can suppose that Hep3B cells expressing CXCR4 may secret stromal cell-derived factor-1 in an autocrine manner. In addition, it was reported that overexpression of CXCR4 enhanced the migration of mesenchymal stem cells. 38 In another study, receptors for chemoattractant factors, including c-Kit, CXCR4, VEGFR1 and VEGFR2, were expressed in HB1.F3. 21 Therefore, these chemoattractant molecules and their respective receptors may have a role in the tumor-tropic effects that enable GESTECs to selectively deliver a suicide enzyme to the tumor. These factors also have important roles in the biology of liver cancer. 39--41 Further study is required to confirm the role of these genes in the mechanisms of tumor cell recognition and/or tumor tropism by GESTECs.
Although 5-FU, a potent inhibitor of thymidylate synthetase, has been used in the treatment of cancer patients over the past few decades, systemic application of 5-FU has been limited by its toxic effects, including myelosuppression and stomatitis, which can occur before achieving a therapeutic response. 42 Therefore, the non-toxic metabolite 5-FC, which is converted to 5-FU by E. coli CD, has received much attention in the last few years. 21, 43 In this study, treatment with 5-FC resulted in decreased cell growth with increasing numbers (8000--24 000 cells per well) of HB1.F3.CD cells co-cultured with Hep3B cells, indicating that the CD/5-FC GEPT system may have potential as a therapy for the treatment of liver cancer. As an earlier report showed that a small number of CDtransfected cells can produce antitumor effects through a bystander effect, 44 we examined whether the number of GESTECs is important for modulating proliferation of liver cancer cells. Different numbers of GESTECs were co-cultured with Hep3B cells, and we also treated the Hep3B cells with 5-FC at various concentrations (100--500 mg ml 
